Small cell carcinoma of the uterine cervix in pregnancy: A case report and review of the literature

Abstract

Abstract. The occurrence of cervical cancer during pregnancy is extremely rare, particularly small cell carcinoma. Small cell cervical carcinoma (SCCC) is a neuroendocrine tumor with a poor prognosis. This study presents the case of an 18-year-old female with stage IB2 SCCC complicated by pregnancy, who was treated with chemotherapy and radiotherapy. The patient was diagnosed shortly after giving birth, and is the youngest female case to be reported in the world. The patient was treated with cisplatin and etoposide chemotherapy and radiotherapy. Complete remission was achieved following neoadjuvant chemotherapy and radiotherapy, and the patient remains in clinical remission eight months following treatment. Cytological screening, colposcopy and if necessary, biopsy, and selective conization at 14-20 weeks should be considered in the patient evaluation.

Differential expression of neuroendocrine markers, TTF-1, p53, and Ki-67 in cervical and pulmonary small cell carcinoma

“…Although Syn and CgA were commonly used immnunohistochemical markers for diagnosis of SCC, different positive rates of each antibody were reported either in cervical SCC or in pulmonary SCC in different studies. [ 16 , 17 ] It was found that Syn had higher expression in the cervical SCC than in the pulmonary SCC in this research, which might be caused by the deviation of specimen selection.…”

Small Cell Cervical Carcinoma in Pregnancy: Therapeutic Options for an Aggressive Cancer Diagnosis

“…Wang et al and Balderston et al reported complete remission with a combination of chemotherapy and radiation therapy in lieu of radical surgery, with Balderston et al utilizing a regimen of cisplatin/etoposide alternated with vincristine/dactinomycin/ cyclophosphamide. 16,17 Given the paucity of data on small cell cervical carcinoma in pregnancy, no standard treatments have been identified.…”

A transient increase and subsequent sharp decrease of chemo‐refractory liver‐metastasized uterine cervical small cell carcinoma to autologous formalin‐fixed tumor vaccine plus anti‐PD‐1 antibody

“…The 5-year disease-specific survival in stage I-IIA, IIB-IVA, and IVB disease was 36.8%, 9.8%, and 0%, respectively [3]. Because of its rarity, no standardized treatment has been established for this carcinoma and therefore intensive chemotherapy and/or chemoradiotherapy similar to that used for lung small cell carcinoma have been applied with only modest success [3][4][5][6]. The present case was refractory to platinum-based chemotherapy, and the patient strongly desired new treatments in addition to radiation therapy of the pelvic lymph node metastases, and we administered both AFTV and anti-PD-1 antibody, although these drugs are still unauthorized for cervical cancer in Japan.…”